Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:ONC NASDAQ:RVMD NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$92.22+3.0%$94.55$79.52▼$124.00$22.63B1.321.05 million shs901,627 shsONCBeOne Medicines$262.68-0.5%$296.83$239.25▼$385.22$28.96B0.49267,266 shs364,255 shsRVMDRevolution Medicines$157.77+0.8%$143.13$34.00▼$166.50$33.29B1.42.76 million shs2.23 million shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.65$60.50▼$106.93$9.21B0.052.58 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.43%+3.47%-0.06%-0.56%-15.83%ONCBeOne Medicines-1.60%-1.58%-10.01%-6.51%-0.19%RVMDRevolution Medicines-2.17%+4.70%+7.50%+59.60%+293.71%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%0.00%0.00%+15.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$92.22+3.0%$94.55$79.52▼$124.00$22.63B1.321.05 million shs901,627 shsONCBeOne Medicines$262.68-0.5%$296.83$239.25▼$385.22$28.96B0.49267,266 shs364,255 shsRVMDRevolution Medicines$157.77+0.8%$143.13$34.00▼$166.50$33.29B1.42.76 million shs2.23 million shsVRNAVerona Pharma PLC American Depositary Share$106.91$106.65$60.50▼$106.93$9.21B0.052.58 million shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.43%+3.47%-0.06%-0.56%-15.83%ONCBeOne Medicines-1.60%-1.58%-10.01%-6.51%-0.19%RVMDRevolution Medicines-2.17%+4.70%+7.50%+59.60%+293.71%VRNAVerona Pharma PLC American Depositary Share0.00%0.00%0.00%0.00%+15.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.5641.93% UpsideONCBeOne Medicines 2.93Moderate Buy$390.0049.26% UpsideRVMDRevolution Medicines 3.00Buy$123.72-21.52% DownsideVRNAVerona Pharma PLC American Depositary Share 2.00Hold$121.7513.88% UpsideCurrent Analyst Ratings BreakdownLatest VRNA, RVMD, ONC, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/4/2026ONCBeOne Medicines Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/2/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$425.00 ➝ $436.006/2/2026RVMDRevolution Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00 ➝ $182.006/1/2026RVMDRevolution Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$169.00 ➝ $195.006/1/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/1/2026RVMDRevolution Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00 ➝ $195.006/1/2026BNTXBioNTech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026BNTXBioNTech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$117.00 ➝ $135.005/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$151.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$96.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.81B8.23$1.34 per share68.01$96.59 per share0.95ONCBeOne Medicines$5.34B5.37$3.81 per share68.62$39.77 per share6.57RVMDRevolution MedicinesN/AN/AN/AN/A$8.44 per shareN/AVRNAVerona Pharma PLC American Depositary Share$42.28M217.94N/AN/A$2.56 per share41.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)ONCBeOne Medicines$286.93M$4.4758.4324.74N/A8.94%12.06%6.69%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,563.67N/A-36.62%-21.12%-9.07%N/ALatest VRNA, RVMD, ONC, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTech$1.531.68%N/AN/A N/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74ONCBeOne Medicines0.203.643.27RVMDRevolution Medicines0.196.806.80VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%ONCBeOne Medicines48.55%RVMDRevolution Medicines94.34%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%ONCBeOne Medicines6.19%RVMDRevolution Medicines7.60%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ARVMDRevolution Medicines250212.60 million196.44 millionOptionableVRNAVerona Pharma PLC American Depositary Share3086.19 million82.06 millionOptionableVRNA, RVMD, ONC, and BNTX HeadlinesRecent News About These CompaniesVerona Pharma Shareholders Approve Merck AcquisitionNovember 6, 2025 | theglobeandmail.comVerona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on MondayNovember 1, 2025 | defenseworld.netDVerona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to SuspendOctober 8, 2025 | msn.comVerona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD PortfolioSeptember 30, 2025 | insidermonkey.comHere’s What Lifted Verona Pharma (VRNA) in Q2September 25, 2025 | insidermonkey.comShareholders of Verona Pharma Approve Proposed Acquisition by MerckSeptember 24, 2025 | globenewswire.comVerona Pharma (VRNA) Rebounded from Challenging Q1September 16, 2025 | msn.comVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025September 16, 2025 | globenewswire.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12, 2025 | insidermonkey.comHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s AcquisitionAugust 28, 2025 | finance.yahoo.comAll You Need to Know About Verona Pharma (VRNA) Rating Upgrade to BuyAugust 12, 2025 | zacks.comJames Aloysius Brady Sells 824 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | insidertrades.comVolatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA StocksJuly 30, 2025 | zacks.comMerck’s $10B Verona Deal: A High-Stakes Play in Respiratory CareJuly 29, 2025 | msn.comWeathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA NowJuly 16, 2025 | zacks.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15, 2025 | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15, 2025 | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15, 2025 | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14, 2025 | globenewswire.comVERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNAJuly 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthBy Leo Miller | June 10, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?By Sam Quirke | June 6, 2026AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility WarningBy Jessica Mitacek | June 10, 2026If the Market Rally Stalls, This ETF Can Insulate PortfoliosBy Jessica Mitacek | May 28, 2026VRNA, RVMD, ONC, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$92.22 +2.72 (+3.04%) Closing price 04:00 PM EasternExtended Trading$92.36 +0.14 (+0.15%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.BeOne Medicines NASDAQ:ONC$262.68 -1.24 (-0.47%) Closing price 04:00 PM EasternExtended Trading$262.71 +0.03 (+0.01%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Revolution Medicines NASDAQ:RVMD$157.77 +1.19 (+0.76%) Closing price 04:00 PM EasternExtended Trading$159.75 +1.98 (+1.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
